The quick answer
If you want the short version: Mounjaro (tirzepatide) produces more weight loss on average than Ozempic (semaglutide). Clinical trials show approximately 22.5% body weight loss with Mounjaro's highest dose versus approximately 14.9% with Ozempic's highest dose. Both work. Both are safe. Both cost roughly the same at branded prices, and compounded versions of both are available at a fraction of the cost.
But the quick answer misses the nuance that actually matters for your decision. Individual responses vary widely. Some patients lose more weight on semaglutide than tirzepatide. Side effect profiles differ slightly. Insurance coverage varies between the two. Your metabolic profile, your physician's experience, and your specific goals all influence which one is better for you. This guide breaks down every dimension of the comparison so you can have an informed conversation with your physician.
What they are: the molecular difference
Understanding the difference between these two medications starts at the molecular level, because the mechanism of action is what drives the clinical differences in outcomes.
Ozempic (semaglutide)
Ozempic is the brand name for semaglutide, manufactured by Novo Nordisk. Semaglutide is a GLP-1 receptor agonist, meaning it mimics the GLP-1 hormone your body naturally produces after eating. GLP-1 does several things: it stimulates insulin secretion, suppresses glucagon (which raises blood sugar), slows gastric emptying (so you feel full longer), and acts on appetite centers in the brain to reduce hunger. Ozempic is FDA-approved for type 2 diabetes. The higher-dose formulation marketed specifically for weight loss is called Wegovy.
Mounjaro (tirzepatide)
Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly. Tirzepatide is a dual GLP-1 and GIP receptor agonist. This is the critical difference. In addition to everything semaglutide does through GLP-1 activation, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP enhances insulin sensitivity, promotes fat metabolism, and appears to have additive effects on appetite suppression when combined with GLP-1 activation. This dual mechanism is believed to be the reason tirzepatide produces greater weight loss in clinical trials. The weight-loss-specific formulation of tirzepatide is marketed as Zepbound.
Weight loss comparison: the clinical trial data
The most rigorous way to compare these medications is through their respective Phase 3 clinical trial programs. While these trials were not direct head-to-head comparisons (with one exception), the study designs were similar enough to draw meaningful comparisons.
Mounjaro: SURMOUNT trials
The SURMOUNT-1 trial enrolled 2,539 adults with obesity or overweight with at least one weight-related comorbidity. At 72 weeks, the results by dose were:
| Tirzepatide Dose | Mean Weight Loss | Patients Losing ≥20% |
|---|---|---|
| 5 mg | -15.0% | 35% |
| 10 mg | -19.5% | 50% |
| 15 mg | -22.5% | 57% |
| Placebo | -2.4% | 1.5% |
Ozempic: STEP trials
The STEP 1 trial enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity. At 68 weeks, the results were:
| Semaglutide Dose | Mean Weight Loss | Patients Losing ≥20% |
|---|---|---|
| 2.4 mg (Wegovy) | -14.9% | 32% |
| Placebo | -2.4% | 1.7% |
The headline numbers favor Mounjaro clearly. At the highest doses, tirzepatide produces roughly 50% more weight loss than semaglutide. The proportion of patients achieving clinically significant weight loss (20% or more) is also substantially higher with tirzepatide. However, these are averages. Individual response varies, and semaglutide has a longer real-world track record with millions of patients and more published cardiovascular outcome data.
Cost comparison
For most patients, especially those without insurance coverage for weight management medications, cost is the deciding factor. Here is how the numbers break down:
| Option | Semaglutide | Tirzepatide |
|---|---|---|
| Branded (diabetes) | ~$935/mo (Ozempic) | ~$1,023/mo (Mounjaro) |
| Branded (weight loss) | ~$1,349/mo (Wegovy) | ~$1,059/mo (Zepbound) |
| Compounded | $150-300/mo | $200-400/mo |
| With insurance | $25-150/mo | $25-150/mo |
At branded prices, the cost difference between the two is not large enough to be a deciding factor. Where cost becomes relevant is in the compounded market: compounded semaglutide is generally $50-100 per month cheaper than compounded tirzepatide. For a comprehensive breakdown of how to get GLP-1 medications at the lowest cost, see our cheapest GLP-1 guide.
Side effects comparison
Both semaglutide and tirzepatide share the same primary side effect profile because they both activate GLP-1 receptors. The gastrointestinal effects are the most common and the reason slow dose titration is essential for both medications.
The most frequently reported side effects for both medications include nausea (particularly in the first few weeks and after dose increases), vomiting, diarrhea, constipation, and abdominal discomfort. These effects are dose-dependent and typically diminish as the body adjusts to each dose level.
Clinical data suggests that Mounjaro may cause slightly more nausea during the initial titration period compared to Ozempic. This is plausible given the dual receptor mechanism — activating both GLP-1 and GIP pathways produces a stronger metabolic signal that the body needs time to adapt to. However, the difference in discontinuation rates due to side effects is not dramatically different between the two medications, suggesting that most patients tolerate either option when titrated slowly.
Both medications carry rare but serious risk considerations including pancreatitis, gallbladder disease, and a theoretical risk of medullary thyroid carcinoma (based on animal studies, not confirmed in humans). These risks apply equally to both medications. For a detailed breakdown of GLP-1 side effects and how to manage them, see our semaglutide side effects guide.
Dosing comparison
Both medications are administered as once-weekly subcutaneous injections using auto-injector pens. The dosing schedules follow a titration pattern where you start at the lowest dose and increase gradually to minimize side effects.
Ozempic / Wegovy (semaglutide) dosing
Semaglutide is titrated from 0.25 mg weekly up to a maximum of 2.4 mg weekly for weight management (Wegovy). The standard titration schedule increases the dose every four weeks: 0.25 mg for weeks 1-4, 0.5 mg for weeks 5-8, 1.0 mg for weeks 9-12, 1.7 mg for weeks 13-16, and 2.4 mg from week 17 onward. For diabetes (Ozempic), the maximum dose is 2.0 mg weekly.
Mounjaro / Zepbound (tirzepatide) dosing
Tirzepatide is titrated from 2.5 mg weekly up to a maximum of 15 mg weekly. The standard titration increases every four weeks: 2.5 mg for weeks 1-4, 5 mg for weeks 5-8, 7.5 mg for weeks 9-12, 10 mg for weeks 13-16, 12.5 mg for weeks 17-20, and 15 mg from week 21 onward. In practice, many patients achieve their target weight loss at 10 mg or 12.5 mg and do not need to titrate to the maximum dose.
Which one should you choose?
The honest answer is that your physician should make this recommendation based on your individual profile. But here are the factors that typically drive the decision:
Choose Mounjaro (tirzepatide) if: Your primary goal is maximum weight loss. You have significant insulin resistance or type 2 diabetes alongside obesity. You can afford the slightly higher compounded price or have insurance coverage. You have not responded adequately to semaglutide. You want the dual GLP-1/GIP mechanism for potentially broader metabolic benefits.
Choose Ozempic (semaglutide) if: Cost is your primary concern and compounded semaglutide is more accessible. You want a medication with a longer real-world track record and more published safety data. You are using it primarily for diabetes management and want the cardiovascular outcome data that semaglutide has. You prefer the option with slightly lower nausea during titration. You want to explore oral options, since oral semaglutide (Rybelsus) is already available.
Regardless of which medication you choose, the fundamentals remain the same: you need a qualified physician managing your protocol, you need regular lab monitoring, and you need to pair the medication with lifestyle modifications for optimal and sustainable results. Explore your options through GLP-1 providers near you or see how to get Mounjaro online or find tirzepatide near you.
Beyond Ozempic and Mounjaro: what is coming next
The GLP-1 landscape is evolving rapidly. While Ozempic and Mounjaro dominate the current market, the next generation of medications is already in clinical trials and the results suggest even greater efficacy.
Retatrutide is the most anticipated next-generation compound. Developed by Eli Lilly, retatrutide is a triple agonist that activates GLP-1, GIP, and glucagon receptors simultaneously. In Phase 2 trials, retatrutide produced up to 24.2% body weight loss at 48 weeks, with some dose groups on track for even greater reductions. The glucagon receptor activation adds direct fat burning and energy expenditure effects that the current dual agonists do not provide. Phase 3 trials are underway with results expected to support regulatory filing. For a detailed breakdown, see our retatrutide guide.
The competitive landscape also includes oral formulations of both semaglutide and tirzepatide, which will eliminate the injection barrier that currently deters many patients. Oral tirzepatide showed 17.4% weight loss at 36 weeks in the OASIS-1 trial. Small molecule GLP-1 agonists like orforglipron from Eli Lilly could further democratize access by simplifying manufacturing and reducing costs.
The bottom line: whether you start with semaglutide or tirzepatide today, you are entering a therapeutic space that is rapidly improving. Your physician can help you transition to newer options as they become available. For a full overview of all weight management options, see our Weight Loss Medications Guide.